Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
2.310
-0.010 (-0.43%)
At close: Nov 20, 2024, 4:00 PM
2.349
+0.039 (1.68%)
After-hours: Nov 20, 2024, 7:02 PM EST
Protara Therapeutics Employees
As of December 31, 2023, Protara Therapeutics had 27 total employees, including 26 full-time and 1 part-time employees. The number of employees increased by 2 or 8.00% compared to the previous year.
Employees
27
Change (1Y)
2
Growth (1Y)
8.00%
Revenue / Employee
n/a
Profits / Employee
-$1,557,333
Market Cap
47.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 27 | 2 | 8.00% |
| Dec 31, 2022 | 25 | -6 | -19.35% |
| Dec 31, 2021 | 31 | 4 | 14.81% |
| Dec 31, 2020 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Burning Rock Biotech | 786 |
| LakeShore Biopharma | 758 |
| BGM Group | 298 |
| Apyx Medical | 252 |
| Rapid Micro Biosystems | 193 |
| Affimed | 76 |
| CollPlant Biotechnologies | 75 |
| Milestone Scientific | 17 |
TARA News
- 5 days ago - Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology - GlobeNewsWire
- 15 days ago - Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 4 weeks ago - Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - GlobeNewsWire
- 2 months ago - Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - GlobeNewsWire
- 2 months ago - Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - GlobeNewsWire
- 2 months ago - Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit - GlobeNewsWire